175
Participants
Start Date
August 29, 2016
Primary Completion Date
July 22, 2017
Study Completion Date
March 15, 2018
ipragliflozin
Oral administration once daily
Placebo
Oral administration once daily
Insulin Therapy
Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
Site JP00005, Aichi
Site JP00028, Aichi
Site JP00003, Chiba
Site JP00013, Chiba
Site JP00035, Chiba
Site JP00022, Fukuoka
Site JP00023, Fukuoka
Site JP00031, Fukuoka
Site JP00002, Gunma
Site JP00011, Gunma
Site JP00006, Hiroshima
Site JP00033, Hokkaido
Site JP00034, Hokkaido
Site JP00021, Hyōgo
Site JP00009, Ibaraki
Site JP00010, Ibaraki
Site JP00004, Kanagawa
Site JP00015, Kanagawa
Site JP00016, Kanagawa
Site JP00019, Mie
Site JP00008, Nagasaki
Site JP00024, Nagasaki
Site JP00025, Nagasaki
Site JP00032, Nagasaki
Site JP00026, Niigata
Site JP00020, Osaka
Site JP00029, Osaka
Site JP00036, Osaka
Site JP00012, Saitama
Site JP00017, Shizuoka
Site JP00018, Shizuoka
Site JP00001, Tochigi
Site JP00030, Tokushima
Site JP00014, Tokyo
Site JP00027, Toyama
Site JP00007, Yamaguchi
Lead Sponsor
Astellas Pharma Inc
INDUSTRY